Developing cell culture-derived pandemic vaccines.
The growing prospect of avian influenza viruses achieving sustained interhuman transmission, combined with the recent emergence of a novel swine-origin A/H1N1 influenza strain, has brought the issue of influenza vaccine production capacity into sharp focus. It is becoming increasingly clear that traditional egg-based manufacturing processes may be insufficient to meet global vaccine demands in a pandemic situation that is caused by a highly pathogenic influenza virus. This review introduces the concepts of modern, cell culture-derived influenza vaccines and their manufacture, and explains the advantages of these vaccines in terms of both speed and efficiency of production as well as immunogenic efficacy. Vaccine production technologies using the mammalian cell lines Vero, MDCK and PER.C6, as well as the baculovirus/insect cell platform, are described in detail. Clinical data are provided from cell culture-derived vaccines that are at an advanced stage of development, and insights are provided into recent developments in the preclinical evaluation of more experimental technologies.
Barrett
P Noel
PN
Baxter BioScience, Global R&D, Biomedical Research Centre, Orth/Donau, Austria. noel_barrett@baxter.com
Portsmouth
Daniel
D
Ehrlich
Hartmut J
HJ
D000818:Animals; D018929:Cell Culture Techniques; D004196:Disease Outbreaks / Q000517:prevention & control; D014943:Global Health; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000737:chemistry / Q000254:growth & development; D053124:Influenza A Virus, H5N1 Subtype / Q000737:chemistry / Q000254:growth & development; D007252:Influenza Vaccines / Q000737:chemistry* / Q000378:metabolism; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control*; D011200:Poultry
D007252:Influenza Vaccines